Clinical Trial Update: CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML [Phase 1, Phase 2]

View source ↗

Summary

This entry reports a clinical trial update for CAR-pNK cell immunotherapy in relapsed/refractory CD33+ acute myeloid leukemia. The trial spans Phase 1 and Phase…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Without Maturation
• Acute Myeloid Leukemia with Maturation

Drugs mentioned

• CAR-pNK Cell Immunotherapy

Snippet

Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Conditions: Acute Myelogenous Leukemia, Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: UNKNOWN